Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28530478 | 1.00 | JAK1 (0.45) | JAK1JAK2TYK2JAK3GAA | |
| SCHEMBL23852777 | 0.81 | PBK (0.48) | JAK1JAK2DRD2PBK | |
| SCHEMBL21774872 | 0.79 | EPHX1 (0.34) | JAK1JAK2TYK2JAK3PBK | |
| SCHEMBL21774870 | 0.79 | EPHX1 (0.34) | JAK1JAK2TYK2JAK3PBK | |
| SCHEMBL12528085 | 0.78 | CKS1B (0.47) | JAK1JAK2TYK2JAK3GAA | |
| SCHEMBL23108060 | 0.78 | JAK1 (0.47) | JAK1JAK2TYK2JAK3GAA | |
| SCHEMBL30772750 | 0.78 | JAK1 (0.49) | JAK1JAK2TYK2JAK3GAA | |
| SCHEMBL12193421 | 0.77 | BTK (0.39) | GAAKDM1AMAOBBTKEPHX1 | |
| SCHEMBL3702152 | 0.76 | BTK (0.61) | GAAKDM1AMAOBBTKDRD2 | |
| SCHEMBL10343938 | 0.76 | BTK (0.61) | GAAKDM1AMAOBBTKDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210379069-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2021-12-09 | — | — | US | disclosed |
| CN-112566697-A | Pyrrolo [1,2-b ] pyridazine derivatives as IRAK4 inhibitors | 吉利德科学公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20200071333-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | JAK1 169/4885JAK2 137/4885TYK2 203/4885 |
| US-20200071333-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | JAK1 169/4885JAK2 137/4885TYK2 203/4885 |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | JAK1 4543/4885JAK2 4667/4885TYK2 4161/4885 |
| US-20210379069-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | JAK1 4543/4885JAK2 4667/4885TYK2 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.